Phaseline

Targets › TGFB1

TGFB1 (Transforming growth factor beta-1 proprotein [Cleaved into: Latency-associated peptide): drug programs, companies and trials

18 programs from 17 companies in 45 trials: 22 Phase 2, 14 Phase 1, 8 Phase 3, 1 Phase 4; Oncology, Hematology, Other; next expected readout Dec 2026.

Transforming growth factor beta-1 proprotein: Precursor of the Latency-associated peptide (LAP) and Transforming growth factor beta-1 (TGF-beta-1) chains, which constitute the regulatory and active subunit of TGF-beta-1, respectively..; FUNCTION: [Latency-associated peptide]: Required to maintain the Transforming growth factor beta-1 (TGF-beta-1) chain in a latent state during storage in extracellular matrix.…. (UniProt, P01137)

Open in Phaseline: the race on TGFB1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Bristol-Myers SquibbLuspatercept (ACE-536)
Transforming growth factor beta inhibitor
TGFB1, TGFB2, TGFB3Phase 4Anemia; Myelodysplastic Syndromes; Beta-thalassemia; CCUS Clonal Cytopenia of Undetermined Significance …Jul 2027
Bristol-Myers SquibbLuspatercept (ACE-536)
Transforming growth factor beta inhibitor
TGFB1, TGFB2, TGFB3Phase 3Myelodysplastic Syndromes; Myelodysplastic Syndromes (MDS); Myeloproliferative Disorders; Beta-ThalassemiaSep 2027
Shanghai Chia Tai Tianqing Pharmaceutical Technology DevelopmentTQB2868 Injection
PD-L1 and TGF-β dual antibody
CD274, TGFB1Phase 3Metastatic Pancreatic Ductal AdenocarcinomaMay 2028
Kolon TissueGeneTG-C (TissueGene-C)
Non-transduced human chondrocytes combined with irradiated transduced human GP2-293 cells
TGFB1Phase 3Degenerative Osteoarthritis–
National Cancer Institute (NCI)Bintrafusp Alfa (M7824)
Programmed cell death 1 ligand 1 binding agent; Transforming growth factor beta binding agent
CD274, TGFB1, TGFB2, TGFB3Phase 2Thymic Epithelial Tumor; Cancer Of Prostate; Kaposi Sarcoma; Urothelial CancerDec 2026
Bruno BockornyAGEN1423
Anti-CD73-TGFβ-Trap bifunctional antibody
NT5E, TGFB1Phase 2Advanced Pancreatic Ductal AdenocarcinomaApr 2027
The First Affiliated Hospital of Zhengzhou UniversitySHR1701
PD-L1 and TGFβ dual inhibitor
PDCD1LG2, TGFB1Phase 2Advanced Gastric CancerJul 2027
SirnaomicsSTP705
siRNA targeting TGF-β1 and COX-2 for inflammation and adipose tissue remodeling inhibition
TGFB1, PTGS2Phase 2Submental FullnessJul 2027
Bicara TherapeuticsFicerafusp alfa (BCA101)
Bispecific antibody targeting EGFR and TGF-β
EGFR, TGFB1Phase 2Metastatic Head and Neck Squamous Cell Carcinoma; Head and Neck Squamous Cell Carcinoma; Head and Neck Squamous Cell Carcinoma (HNSCC); Squamous Cell Carcinoma of Head and Neck (SCCHN)Oct 2027
The First Affiliated Hospital with Nanjing Medical UniversityRetlirafusp alfa
Anti-PD-L1/TGF-β bifunctional fusion protein
PDCD1L1, TGFB1Phase 2Intrahepatic Cholangiocarcinoma (Icc)Mar 2028
University of Alabama at BirminghamPirfenidone
Antifibrotic agent; reduces TGF-β signaling and inflammatory pathways
TGFB1Phase 2Recurrent Acute PancreatitisSep 2028
New Approaches to Neuroblastoma Therapy ConsortiumUniversal Donor (UD) TGFβi NK Cells
TGFβ-inhibited universal donor natural killer cells
TGFB1Phase 2NeuroblastomaDec 2028
FBD BiologicsHCB301
Engineered SIRPα fused to anti-PD-L1 and TGF-β fusion protein
SIRPA, PDCD1LG2, TGFB1Phase 1Advanced Solid TumorDec 2026
National Institute of Allergy and Infectious Diseases (NIAID)Pirfenidone
TGF-beta pathway inhibitor
TGFB1Phase 1Multiple SclerosisJan 2027
Nationwide Children's HospitalUniversal Donor Natural Killer Cells (UD-NK)
Ex vivo expanded natural killer cells with TGF-beta inhibition
TGFB1Phase 1Acute Myeloid Leukemia; High Grade GliomaFeb 2027
Kari KendraUD TGFbetai NK cells
TGF-beta inhibitor-engineered natural killer cells
TGFB1Phase 1Clinical Stage IV Cutaneous Melanoma AJCC v8Apr 2027
Second Affiliated Hospital of Guangzhou Medical UniversityGPC3 and/or TGFβ targeting CAR-T cells
Engineered CAR-T cells targeting GPC3 and/or TGFβ with knockdown of PD1/HPK1, enhanced wit
GPC3, TGFB1Phase 1Hepatocellular CarcinomaAug 2029
Baylor College of MedicineDNR.NPC-specific T cells
TGF-beta resistant EBV-specific cytotoxic T-lymphocytes
TGFB1Phase 1EBV-positive Nasopharyngeal CarcinomaFeb 2033

Conditions

Myelodysplastic Syndromes (8) Anemia (3) Metastatic Head and Neck Squamous Cell Carcinoma (2) Advanced Pancreatic Ductal Adenocarcinoma (1) Submental Fullness (1) Thymic Epithelial Tumor (1) Cancer Of Prostate (1) Kaposi Sarcoma (1) Urothelial Cancer (1) Advanced Solid Tumor (1) Clinical Stage IV Cutaneous Melanoma AJCC v8 (1) Degenerative Osteoarthritis (1)

Modalities

small molecule (8), mixed (4), other (3), antibody (2), protein or peptide (1)

Companies

Bristol-Myers Squibb (2) Bruno Bockorny (1) Sirnaomics (1) National Cancer Institute (NCI) (1) FBD Biologics (1) Kari Kendra (1) Kolon TissueGene (1) Shanghai Chia Tai Tianqing Pharmaceutical Technology Development (1) Nationwide Children's Hospital (1) Baylor College of Medicine (1) Second Affiliated Hospital of Guangzhou Medical University (1) The First Affiliated Hospital with Nanjing Medical University (1) The First Affiliated Hospital of Zhengzhou University (1) Bicara Therapeutics (1) New Approaches to Neuroblastoma Therapy Consortium (1) National Institute of Allergy and Infectious Diseases (NIAID) (1) University of Alabama at Birmingham (1)

Related targets

TGFB2 (3) TGFB3 (3) CD274 (2) PDCD1LG2 (2) NT5E (1) PTGS2 (1) SIRPA (1) GPC3 (1) PDCD1L1 (1) EGFR (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.